Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 305,100 | 54,500 | 62,700 | 82,600 | 51,800 |
| Depreciation Amortization | 118,000 | 113,700 | 63,100 | 44,300 | 38,200 |
| Income taxes - deferred | -2,400 | -1,100 | 8,600 | 3,300 | 5,200 |
| Accounts receivable | 49,000 | -8,200 | -94,200 | -4,800 | -22,400 |
| Accounts payable and accrued liabilities | 18,700 | 16,500 | -7,000 | 16,100 | -14,800 |
| Other Working Capital | 8,800 | -58,400 | -119,300 | 53,700 | -44,300 |
| Other Operating Activity | 38,800 | 71,000 | 127,900 | 12,900 | 40,900 |
| Operating Cash Flow | $536,000 | $188,000 | $41,800 | $208,100 | $54,600 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -141,000 | -86,900 | -69,500 | -54,800 | -76,200 |
| Net Acquisitions | N/A | N/A | -827,700 | -195,100 | N/A |
| Other Investing Activity | -10,000 | -10,000 | 0 | 0 | 0 |
| Investing Cash Flow | $-151,000 | $-96,900 | $-897,200 | $-249,900 | $-76,200 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 435,900 | 118,700 | 798,000 | 0 | 0 |
| Debt Repayment | -373,000 | -105,000 | -2,800 | 0 | 0 |
| Common Stock Issued | N/A | N/A | N/A | 19,300 | 17,100 |
| Common Stock Repurchased | N/A | N/A | -100 | -33,100 | 0 |
| Other Financing Activity | 6,600 | -49,600 | -6,400 | -37,600 | -36,900 |
| Financing Cash Flow | $69,500 | $-35,900 | $788,700 | $-51,400 | $-19,800 |
| Exchange Rate Effect | -1,000 | 400 | -200 | 0 | 100 |
| Beginning Cash Position | 168,000 | 112,400 | 179,300 | 272,500 | 312,800 |
| End Cash Position | 621,500 | 168,000 | 112,400 | 179,300 | 271,500 |
| Net Cash Flow | $453,500 | $55,600 | $-66,900 | $-93,200 | $-41,300 |
| Free Cash Flow | |||||
| Operating Cash Flow | 536,000 | 188,000 | 41,800 | 208,100 | 54,600 |
| Capital Expenditure | -141,000 | -86,900 | -72,100 | -54,800 | -76,200 |
| Free Cash Flow | 395,000 | 101,100 | -30,300 | 153,300 | -21,600 |